I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Leonid Timashev reaffirmed a Buy rating on Biohaven Ltd. (BHVN) with a $23 price target, noting the stock closed at $14.54. Bank of America also issued a Buy rating, while William Blair reiterated a Hold rating on the same day.
RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. yesterday and set a price target of $23.00. The company’s shares closed yesterday at $14.54.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Timashev is a 5-star analyst with an average return of 27.1% and a 64.95% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Alkermes, and Revolution Medicines.
In addition to RBC Capital, Biohaven Ltd. also received a Buy from Bank of America Securities’s Dina Ramadane in a report issued yesterday. However, today, William Blair reiterated a Hold rating on Biohaven Ltd. (NYSE: BHVN).